Tarceva (erlotinib): price, analogues. How cheaper to buy Tarceva

The drug "Tarceva", or rather, its main active substance - erlotinib - is a powerful tyrosine kinase inhibitor. This enzyme is present in the epidermal growth factor receptor HER1 / EGFR, and its blocking helps to arrest the growth of a malignant tumor.

According to the results of recent studies, the use of the drug "Tarceva" prolonged life for patients with metastatic lung cancer by almost 42%. In addition, the drug reduces the manifestation of symptoms associated with this pathology - coughing, pain and shortness of breath.

The drug is released only as prescribed by the doctor. It can be purchased in the pharmacy chain, but it is expensive. And the generics of Tarceva are Erlonat and Erlocip, produced under license by the famous Indian companies Natco Pharna Ltd. And Cipla Ltd., are much cheaper.

Where can the drug "Tarceva" buy cheaper

In Russia, generics "Tarceva" from famous Indian manufacturers can be purchased on a special website of a large Indian company with a 5-year-old reputation WWW.ONKO24.COM. The condition for the provision of services is the availability of appropriate documents that can confirm the need for modern treatment.

On the generic tablets "Tarceva" the price is reduced not because of the fact that these drugs are somewhat inferior to the brand. They are manufactured under an official license and under strict quality control. It's just that Indian corporations do not have to invest in technology and research. And this in the end is able to help an ordinary buyer who has fallen into a difficult worldly situation. Therefore, when ordering generics of Tarceva funds on this site, do not be afraid that you will get a fake!

Dosing and Administration

The drug is taken orally, one hour before or two hours after a meal, once a day.

Depending on the diagnosis, the dosage of the "Tarceva" remedy varies:

• In the case of non-small cell lung cancer - 150 mg (at a time);
• When pancreatic cancer is detected, 100 mg is given, in combination with a drug containing gemcitabine.

If necessary, adjust the dose gradually, by 50 mg.

When there are signs of progression of the pathology, treatment with Tarceva should be stopped.

Erlotinib ("Tarceva") in a dose exceeding the recommended dose can cause the patient to have skin rashes, diarrhea and lead to an increase in the level of hepatic enzymes. These manifestations require symptomatic therapy, and treatment with the drug "Tarceva" for this time is suspended.

Contraindications

This remedy is not prescribed for the detection of severe allergies to erlotinib. "Tarceva" is also not shown pregnant and lactating.

Specialists should be cautious, prescribing the drug for violations of the liver, as well as under-18 patients.

Adverse events

In the process of using Tarceva tablets or generics, the following undesirable effects may occur in patients:

• diarrhea;
• nausea and vomiting;
• anorexia;
• Pain in the epigastric region;
• Gastric bleeding (especially in the case of simultaneous use of the drug "Warfarin" or NSAIDs);
• conjunctivitis;
• Keratitis;
• Nasal bleeding;
• Cough and shortness of breath;
• headache;
• Neuropathy;
• Dry skin, itching;
• Decrease in body weight.

Application Features

With the progression of signs of pulmonary pathology (cough, dyspnea and fever), the Tarceva drug is discontinued until the cause is clarified.

Patients at risk of dehydration need control of the number of electrolytes in the blood (potassium, including), as well as monitoring the functioning of the kidneys.

Since Tarceva therapy in some cases led to the development of hepatic insufficiency, during the entire course it is necessary to observe the work of the liver, especially in those patients who have pathologies or get hepatotoxic drugs. In case of detection of severe liver damage, the Tarceva remedy is stopped.

The use of the drug is also impossible in the case of detection of gastrointestinal perforation, with the development of exfoliative or bullous skin lesions, as well as in the case of eye pain or exacerbation of ophthalmic pathological processes.

During the treatment process and at least 14 days after it, women need reliable contraceptives.